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Different dietary sources of folate have differing bioavailabilities, which may affect 
their nutritional “value.” In order to examine if these differences also occur within the 
same food products, a short-term human pilot study was undertaken as a follow-up 
study to a previously published human trial to evaluate the relative native folate 
bioavailabilities from low-fat Camembert cheese compared to pteroylmonoglutamic 
acid as the reference dose. Two healthy human subjects received the test foods in a 
randomized cross-over design separated by a 14-day equilibrium phase. Folate body 
pools were saturated with a pteroylmonoglutamic acid supplement before the first 
testing and between the testings. Folates in test foods and blood plasma were ana-
lyzed by stable isotope dilution assays. The biokinetic parameters Cmax, tmax, and area 
under the curve (AUC) were determined in plasma within the interval of 0–12 h. When 
comparing the ratio estimates of AUC and Cmax for the different Camembert cheeses, 
a higher bioavailability was found for the low-fat Camembert assessed in the present 
study (≥64%) compared to a different brand in our previous investigation (8.8%). It 
is suggested that these differences may arise from the different folate distribution in 
the soft dough and firm rind as well as differing individual folate vitamer proportions. 
The results clearly underline the importance of the food matrix, even within the same 
type of food product, in terms of folate bioavailability. Moreover, our findings add to 
the increasing number of studies questioning the general assumption of 50% bio-
availability as the rationale behind the definition of folate equivalents. However, more 
research is needed to better understand the interactions between individual folate 
vitamers and other food components and the potential impact on folate bioavailability 
and metabolism.
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inTrODUcTiOn
Folates are “key players” in the one-carbon metabolism path-
ways and thus are involved in DNA synthesis, amino acid 
metabolism, and methylations (1). However, mean intake of 
folate in many countries is considered to be below the dietary 
recommendations for humans. Low dietary intake of folate is 
linked with the risk of neural tube defects (2) and is suspected 
to be associated with the development of certain forms of cancer 
(3), Alzheimer’s disease (4), and cardiovascular disease (5). 
Obeid and colleagues concluded in a recently published study 
that there is an epidemic of folic acid-preventable spina bifida 
and anencephaly in Europe and that mandatory fortification 
would improve public health in Germany and other European 
countries (6). Therefore, many countries in the European Union 
favor the consumption of foods endogenously high in folates or 
increasing endogenous folate content in foods. However, apart 
from folate content alone, bioavailability appears to be the chal-
lenge if folate supply from foods is intended to be increased. 
The current dietary recommendations are based on the findings 
of Sauberlich et al. (7), who determined in a long-term human 
study a 50% bioavailability of native folates from foods relative to 
pteroylmonoglutamic acid. This value has since been questioned 
as subsequent studies revealed bioavailabilities of folates, e.g., 
from spinach of 89–113% (8), from citrus fruits and vegetables of 
98% (9) relative to pteroylmonoglutamic acid, or from broccoli 
and strawberries of 99–120% relative to 5-CH3-H4folate (10). 
This prompted us to conduct a recently published human study 
on folate bioavailability by using stable isotope dilution assays 
for analysis of plasma folate and an area under the curve (AUC) 
approach (11). A surprisingly high inter-individual variation in 
folate bioavailability and also highly different bioavailabilities 
of the test foods ranging from 8.8% for Camembert cheese to 
73% for spinach relative to pteroylmonoglutamic acid could be 
observed (12). However, we did not investigate the potential 
variation in folate bioavailability within the same test food, 
e.g., Camembert cheese. Therefore, the aim of the present pilot 
study was to compare the oral bioavailability and biokinetic 
data between pure compound of pteroylmonoglutamic acid as 
the reference and native folate from a low-fat type Camembert 
cheese of a brand different to that used in the aforementioned 
human study (12). The bioavailability data of the cheese, which 
is a popular and significant dietary source of folate in Germany 
(13), were obtained from analyses of 5-CH3-H4folate in plasma 
following oral administration.
MaTerials anD MeThODs
chemicals
The following chemicals were obtained commercially from 
the sources given in parentheses: rat serum (Biozol, Eching, 
Germany), chicken pancreas (Difco, Sparks, MD, USA), acetic 
acid, acetonitrile, sodium phosphate dibasic dihydrate, formic 
acid, hexane, methanol, potassium phosphate monobasic, 
sodium hydroxide, sodium chloride (Merck, Darmstadt, 
Germany), alpha-amylase, ammonium formate, ascorbic acid, 
pteroylmonoglutamic acid, 4-morpholineethanesulfonic acid 
(MES), 2-mercaptoethanol, protease type XIV, sodium acetate 
(Sigma, Deisenhofen, Germany), (6S)-tetrahydrofolic acid, 
calcium (6S)-5-methyltetrahydrofolate, 10-formylfolic acid, and 
(6S)-5-formyltetrahydrofolic acid (Schircks, Jona, Switzerland). 
All chemicals were at least of analytical-reagent grade. [2H4]-
5-methyltetrahydrofolic acid, [2H4]-5-formyltetrahydrofolic 
acid, [2H4]-tetrahydrofolic acid, [2H4]-10-formylfolic acid, and 
[2H4]-pteroylmonoglutamic acid were synthesized as previously 
reported (14).
Test Foods
A low-fat Camembert cheese (16  g fat/100  g) was purchased 
at a local supermarket in the city of Munich, Germany. The 
pteroylmonoglutamic acid solution was prepared by suspend-
ing pteroylmonoglutamic acid (2.0 mg) in tap water, which was 
then alkalized with dilute sodium hydroxide until all solids were 
dissolved and then adjusted to pH 7 with dilute hydrochloric 
acid followed by adjustment to volume (1 L) with tap water. The 
Camembert cheese under study was assessed in two different 
ways: (a) whole cheese samples were frozen in liquid nitrogen and 
homogenized in entirety and (b) cheese samples were segmented 
into rind and dough and analyzed separately by stable isotope 
dilution assays as previously described (15). Quality control 
was performed by assessing recovery, precision, linearity, LOD, 
limit of quantification (LOQ), and the analysis of dried, mixed 
vegetables as certified reference material (16).
Plasma
Plasma samples were analyzed by stable isotope dilution assays 
using phenyl SPE cleanup as detailed by Mönch et  al. (17). 
Briefly, aliquots of plasma (400 μL) were spiked with [2H4]-5-
methyltetrahydrofolic acid (5 ng in MES buffer) and then overlaid 
with ammonium formate buffer (600 μL) and equilibrated for 
30 min at room temperature and subjected to cleanup on phe-
nyl SPE cartridges (Discovery DSC-ph, 100  mg, 1  mL, Varian, 
Darmstadt, Germany). Folates were eluted from SPE columns 
with 0.5 mL of a mixture of aqueous sodium chloride (5%) and 
sodium acetate (100 mmol/L; 1% ascorbic acid). The lower limit 
of quantification (LLOQ) was 0.37 nmol/L.
Pilot study and ethical Permission
Two healthy, non-smoking Caucasian female subjects partici-
pated in the pilot study with a mean (±SD) age of 25.5 (±2.1) 
years and a mean (±SD) body mass index of 20.9 (±2.1) kg/m2. 
Ethical permission was obtained by the Ethics Committee of the 
Friedrich Schiller University Jena, Faculty of Medicine (code 
1415-09/04). The study was carried out in accordance with the 
recommendations of the Ethics Committee given above with 
written informed consent from all subjects. All subjects gave 
written informed consent in accordance with the Declaration 
of Helsinki. To improve the uniformity among the two subjects 
and subsequently the precision of bioavailability estimates, a 
pteroylmonoglutamic acid supplement (800 μg/day = 1.8 μmol/
day) was given for 14 days before the first testing and between 
the testings and was discontinued 2 days prior to the start of 
FigUre 1 | 5-Methyltetrahydrofolate levels in plasma of two volunteers after intake of folic acid solution or camembert cheese.
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the study (12). The study had a randomized cross-over design, 
and each subject had the following experimental treatments 
separated by a 14-day equilibrium phase: 448-nmol total folates 
via Camembert cheese (200 g) and 453-nmol pteroylmonoglu-
tamic acid via orally administered pteroylmonoglutamic acid 
solution (100  mL) serving as reference treatment. After an 
overnight fast, volunteers took the Camembert cheese or drank 
the pteroylmonoglutamic acid solution, respectively, together 
with one slice of toast bread. During the experimental treat-
ment periods (24  h), the consumption of water was allowed 
ad  libitum, and two further standardized and virtually folate-
free study meals consisting of wheat bread (nine slices or 500 g), 
butter (100 g), and honey (250 g) were offered for lunch and 
dinner. Venous blood samples (9  mL) were drawn in EDTA-
coated tubes (Sarstedt, Nuernbrecht, Germany) predose, as well 
as 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h after the administration of 
Camembert cheese or reference solution. Blood was centrifuged 
(10 min/2000 × g/4°C) to separate plasma from red blood cells. 
Plasma was stored frozen at −24°C until further preparation 
and analysis.
Biokinetic calculations
Plasma 5-CH3-H4folate was evaluated. In the first step, the indi-
vidual predose (t = 0 h) 5-CH3-H4folate plasma concentrations 
were subtracted from all subsequent values. Negative concentra-
tions that might result from this procedure were discarded. The 
predose-corrected concentrations were subjected to a standard 
non-compartmental analysis in order to derive Cmax (observed 
maximum plasma concentration), tmax (time of Cmax), and AUC 
(area under the plasma concentration–time curve) (18). The 
calculation of the AUC was done by linear trapezoidal rule and 
was limited within the interval between 0 and 12 h after dose, 
because after 12 h, a somewhat unexpected and marked increase 
up to 24  h after dose occurred (see Figure  1). Concentrations 
below the LLOQ were treated as 0.
resUlTs
For determining the exact folate dose, we analyzed the Camembert 
cheese for individual folate vitamers and found considerably 
lower total folate content and a rather different folate profile 
compared to the Camembert cheese (different brand) assessed 
in our previous study (12). Whereas the latter contained as much 
as 647 nmol/100 g total folate and its major folate vitamer was 
tetrahydrofolate, the total folate content of the Camembert cheese 
in the present study was only 224  nmol/100  g, and its major 
vitamer was 5-formyltetrahydrofolate (Table 1). The time course 
of the 5-CH3-H4folate (non-predose-corrected) concentrations in 
plasma is shown in Figure 1. After intake of Camembert cheese, 
the concentrations increased up to 2–3 h after dose and decreased 
below the predose values to a local minimum at 6 and 8 h after 
dose. Thereafter, the concentrations increased continuously up to 
the next morning, i.e., 24 h after intake, well above the predose 
values. After intake of folic (pteroylmonoglutamic) acid solution, 
TaBle 2 | summary table of baseline corrected 5-ch3-h4folate biokinetic 
parameter in plasma.
Parametera camembert Oral solution
Cmax (nmol/L) 17.3 ± 12.8 (74) 5.11 ± 4.79 (94)
tmax (h) 24 (24, 24) 6 (4, 8)
AUC0–12 (nmol⋅h/L)b 45.9 ± 5.96 (13) 65.0 (n.c.) n.c.
Ratio estimate in % of reference baseline 
corrected and dose-normalizedc
71/65
Doses of the testings were 448 and 453 nmol sum of folates via Camembert cheese 
and oral solution of pteroylmonoglutamic acid, respectively.
Tabulated values are arithmetic mean ± SD (CV%) of n = 2 subjects except for tmax 
where values are median (min, max); n.c., not calculated because AUC was not 
calculated in subject 2; reason: this subject had its last positive, pre–post-dose 
concentration difference at 4 h after dosing.
aCmax and tmax were determined within the 0- to 24-h interval.
bAUC0–12 is the positive AUC within the interval 0–12 h, i.e., concentrations falling below 
the individual predose values were discarded.
cOral solution as reference, percentage based on the mean of AUC0–12/based on the 
subject with valid Camembert and oral solution AUC data.
TaBle 1 | Folate distribution and sum of all folate vitamers in the test foods, mean ±sD (n = 3).
Food Tetrahydrofolate 
(μg/100 g)
5-Methyl-tetrahydrofolate 
(μg/100 g)
5-Formyl-tetrahydrofolate 
(μg/100 g)
10-Formylfolate 
(μg/100 g)
Pteroylmonoglutamic 
acid (μg/100 g)
sum of folates 
(nmol/100 g)
Camembert cheese 
(present study)
17.7 ± 1.8 31.9 ± 4.5 38.6 ± 0.9 6.4 ± 0.6 n.d. 224 ± 18
Camembert cheese (12) 144.7 ± 12.9 46.2 ± 2.2 54.5 ± 4.1 40.2 ± 5.3 n.d. 647 ± 16
n.d., not detectable.
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the curves showed a fluctuating increase with maxima reached 
within the region between 2 and 8 h after dose. At 8 and 12 h 
after dose, concentrations reached a minimum which was below 
the predose values in both subjects, followed by a continuous 
increase up to the next morning. Due to sufficient reducing and 
methylation capacity in intestinal epithelium and the liver, no 
other folate vitamers than 5-CH3-H4folate were detectable in 
circulating plasma. The increase in plasma folate concentration 
at late sampling times after folate dosage was also observed in 
our previous study (12). The suppression of bile production and 
excretion under fasting conditions is most likely the reason for the 
observed increase (19). In order to exclude these obvious effects at 
the last sampling time of 24 h, the kinetic evaluation was limited 
to the range of 0–12 h. Table 2 summarizes the biokinetic param-
eters of predose-corrected 5-CH3-H4folate. The time to attain 
the maximum concentrations (tmax) was highly variable among 
treatments. The results were surprising as the low-fat Camembert 
in the present study showed a much higher folate bioavailability 
(65–71%, c.f. Table 2) than the low-fat Camembert investigated 
in our previous study, when we found a mean bioavailability of 
8.8% for all 24 volunteers (12). However, as both studies were con-
ducted under virtually identical conditions and only a few weeks 
apart and the two volunteers of the present study also participated 
in  the other one, a cross-study comparison [present pilot study vs. 
Ref. (12)] is possible. Both volunteers also revealed a tremendous 
lower folate bioavailability for the other Camembert as low as 9.2 
and 16.4%, respectively, relative to the reference dose of the folic 
acid solution.
DiscUssiOn
The reason for this may be explained by the different folate 
distributions in the two cheeses. The Camembert with the lower 
bioavailability (12) contained most of its folates (80%) in the 
rind, which is a more compact and firm matrix than the dough 
and may render the folates less accessible during gastrointestinal 
digestion. In contrast to this, in the present study, more than 60% 
of the folate vitamers could be found in the relatively soft dough 
matrix. Moreover, the major folate vitamer in the Camembert 
cheese with lower bioavailability was tetrahydrofolate (12), which 
is the least stable vitamer and therefore, particularly susceptible to 
degradation in the gastrointestinal environment (20).
The cross-study comparison [present pilot study vs. Ref. (12)] 
of the Camembert results of the two subjects, who participated 
in both studies, substantiated the different bioavailabilities on an 
intraindividual level (65–71 vs. 9–16%), despite the few volunteers 
in the present investigation. Moreover, as both studies were run 
under virtually identical conditions, they indicated the Camembert 
cheeses (different folate profiles and matrix distribution) as the 
determining factors. Also, the low number of recruited subjects 
in the present study is not unusual for pilot studies investigating 
the bioavailability and metabolism of bioactive food components 
(21, 22) with reported number(s) as low as one (23). However, 
we still want to emphasize that our study is an exploratory and 
limited one as there is only for one volunteer a complete data set.
Nevertheless, our results underline the dependence of folate 
bioavailability on the specific food product/type ingested. The 
reasons for the differences of folate bioavailability are still unclear. 
Previously, we assumed that (a) different kinetics and bioavailabili-
ties of the folate vitamers (24) and particularly of the polyglutamate 
forms, (b) presence of deconjugase inhibitors, and (c) entrapping 
of folates in the food matrix may account for these differences. 
Therefore, the general folate bioavailability from foods of 50% as 
the basis for the definition of folate equivalents must be seriously 
questioned, and its generality requires further investigation. 
Possible approaches are further testing of foods in human studies 
with less expensive designs, such as sampling of dried blood spots 
(25) or the application of in vitro digestion models, which can be 
used as a cost- and time-efficient high throughput “screening tool.” 
The respective investigations are currently in progress.
cOnclUsiOn
Although on a pilot scale, the results of the present study clearly 
demonstrate that a food product (e.g., Camembert cheese) cannot 
be regarded as a homogenous dietary “standard” with a predict-
able folate bioavailability. Mandatory folic acid fortification as 
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successfully implemented in many countries, including the USA 
and Canada (6), is therefore a very efficient strategy to overcome 
these shortcomings in folate bioavailability and subsequently 
bioactivity.
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